

FOUNDATION KIND BETER AT DEN HAAG

Annual Report 2024



Stichting Kind Beter • P.O. box 82048 • 2508 EA Den Haag • The Netherlands +31(0)6-21513762 • kindbeter@ziggo.nl • KVK nummer/Chamber of Commerce: 71725261 RSIN/Tax number: 858824693 • kindbeter.nl



CONTENTS

AUD	ITOR'S REPORT	
1 2	Engagement Compilation report	3 3
1	MANAGEMENT REPORT	4
FIN/	ANCIAL STATEMENTS	
1 2	Balance sheet as at December 31, 2024 Profit and loss account over 2024	7 8
3	Notes to the financial statements	9
4	Notes to the balance sheet as of December 31, 2024	10
5	Notes to the profit and loss account 2024	11



Page



To the management of Foundation Kind Beter Brusselselaan 12 2587 AH The Hague

Reference	Processed by		
19110	WKO		

Date June 23, 2025

Dear management,

We hereby send you the report regarding the financial statements for the year 2024 of the foundation.

1 ENGAGEMENT

In accordance with your instructions we have compiled the annual account 2024 of the foundation, including the balance sheet with counts of \in 38,068 and the profit and loss account with a result of \in 8,902.

2 COMPILATION REPORT

Introduction

In accordance with your instructions we have compiled the financial statements 2024 of Stichting Kind Beter in Den Haag, which comprise the balance sheet as at December 31, 2024, the profit and loss account for 2024 and the notes.

Management's responsibility

The distinctive feature of a compilation engagement is that we compile financial information based on information provided by management of the entity. Management is responsible for the accuracy and completeness of the information provided and the financial statements based thereon.

Confirmation

Based on the information provided to us, we have compiled the financial statements using the accounting policies as included in Part 9 of Book 2 of the Dutch Civil Code.



Stichting Kind Beter, Den Haag

1 MANAGEMENT REPORT

Background:

Our son Fenn was born in 2012. At first, he seemed like an ordinary boy, but it soon became clear that he has a rare condition. The genetic mutation in the FOXP1 gene has only recently been identified, and no fundamental research has yet been carried out to determine its cause or find a potential treatment. Currently, approximately 500 children worldwide have been diagnosed with this genetic variant. The severity of the syndrome varies greatly from child to child.

In collaboration with Leiden University Medical Center (LUMC), a research program has been defined. To enable this, funding had to be secured. The Kind Beter Foundation was established to fulfill this need.

At the end of 2018, we began developing a bilingual website in Dutch and English. Subsequently, we successfully applied for ANBI (Public Benefit Organization) status.

In 2024, the first phase of the research was completed, and organoids were successfully developed by LUMC.

Together with Prof. Dr. Willeke van Roon (LUMC) and an international consortium, we have now secured a major grant of \in 1.3 million. This grant does not run through the Kind Beter Foundation, but it enables further work on advanced organoid technology-miniature versions of human organs that allow for drug testing. The consortium consists of LUMC, Radboudumc, PimBio BV, the University of Heidelberg, and the foundations Kind Beter and Proefdiervrij.

In addition to fundraising, the Kind Beter Foundation also acts as a connector for all patients and caregivers in the Netherlands and Belgium, in collaboration with the international FOXP1 patient organization.

In June 2025, a major global conference for researchers and families will take place, co-organized by the Kind Beter Foundation.

Vision:

We believe that with the right efforts, we can convince others to contribute to finding solutions for rare diseases.

Ambition:

To find a solution for FOXP1 within five to ten years. Due to delays caused by the COVID-19 pandemic, we have had to extend our original five-year timeline. However, our ambition to find a solution remains unchanged.

Primary goals:

- Funding research into the causes and possible cures for the rare FOXP1 syndrome;
- Funding potential medical treatments/medications for FOXP1 syndrome.

Secondary goals:

- Screening for related conditions that could be identified and analyzed through this study;
- Connecting patients, parents, caregivers, and scientists.

General:

To develop and maintain relevant relationships that help realize the above objectives.



Stichting Kind Beter, Den Haag

Organization and governance:

The foundation has no paid staff. The board has remained unchanged since 2018. Board members serve on a voluntary, unpaid basis. We have since been joined by two volunteer fundraisers, Caroline Valk and Sylvia Bos. In addition, a parent couple with a FOXP1 child, Tom Wesseling and Annemiek Linn, are actively working with us.

In conclusion:

We will continue to fight for our ultimate goal: research into FOXP1 and related genetic disorders. Because every child deserves the chance to get better.

- 5 -

Board of the Kind Beter Foundation: Chair - Andre de Koning Secretary - Esther Kloosterman Treasurer - Wilko Korving




FINANCIAL STATEMENTS






1 BALANCE SHEET AS AT DECEMBER 31, 2024 (before appropriation of results)

		December 31, 2024		December 31, 2023	
		€	€	€	€
ASSETS					
Current assets Cash and cash equivalents	(1)		38,068		29,166





	December 31, 2024		December 31, 2023	
	€	€	€	€
(2)		38,068		29,166
	(2)	€	€€	€€€





2 PROFIT AND LOSS ACCOUNT OVER 2024

		2024		2023	
		€	€	€	€
Donations	(3)		9,159		21,216
Expenses					
Other operating expenses	(4)		257		4,170
Result Taxation on result from general			8,902		17,046
operations					
Result			8,902		17,046





Stichting Kind Beter, Den Haag

3 NOTES TO THE FINANCIAL STATEMENTS

Activities

The foundation of Stichting Kind Beter was established by notarial deed on 23 May 2018. The objectives of the Foundation are:

Expanding knowledge with regard to FOXP1 in particular and other related genetic abnormalities. To fund related research and development of gene targeted therapies for FOXP1 and talented syndromes.

GENERAL PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The annual accounts have been prepared in accordance with Guideline 650 for fundraising institutions of the Dutch Council for Annual Reporting.

The annual accounts have been prepared based on the historical cost. Valuation of assets and liabilities and determination of the result takes place under the historical cost convention.

Income and expenses are allocated to the year to which they relate. Profits are only included insofar as they have been realized on the balance sheet date. Liabilities and possible losses that originate before the end of the reporting year are taken into account if they have become known before the preparation of the annual accounts.

ACCOUNTING PRINCIPLES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

PRINCIPLES FOR THE DETERMINATION OF THE RESULT

General

The result is defined as the difference between the revenue from goods delivered and services performed on one hand and, on the other hand, the costs and expenses for that year, valued at historical costs.

Expenses general

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.

- 9





4 NOTES TO THE BALANCE SHEET AS OF DECEMBER 31, 2024

ASSETS

	12/31/2024	12/31/2023
	€	€
1. Cash and cash equivalents		
ING Bank N.V.	38,068	29,166
The cash equivalents are at free disposal.		
EQUITY AND LIABILITIES		

2. Equity

Reconciliation company capital

Consolidated capital	38,068	29,166

- 10 -



5 NOTES TO THE PROFIT AND LOSS ACCOUNT 2024

	2024	2023
	€	€
3. Donations		
Donations	9,159	21,216
Staff		
During the 2024 financial year the company had no employees.		
4. Other operating expenses		
Sales and distribution expenses General expenses	- 257	3,933 237
	257	4,170
Sales and distribution expenses		
Publicity and advertisement	-	3,933
General expenses		
Bank charges	257	237

- 11 -